Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
16/09/2025 13:26
Sept 16 (Reuters) - Adagene Inc 978y.F: ADAGENE EXPANDS SAFEBODY® COLLABORATION AND LICENSE AGREEMENT WITH EXELIXIS TO DEVELOP THIRD NOVEL MASKED ANTIBODY-DRUG CONJUGATE ADAGENE INC - UNDER COLLABORATION, ELIGIBLE FOR MILESTONES AND ROYALTIES Source text: ID:nGNXcdQHfw Further company coverage: [978y.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
Brief: Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
Brief: Adagene Announces Up To $25 Million Strategic Investment From Sanofi